Stagnation in sales to Russia due to the geopolitical impact of the Russia-Ukraine conflict
First written in FY2024-Q1. 2 of 4 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「The diagnostics business was affected by lower sales to Russia and a decline in the number of tests in China, among other factors.」
Lower sales to Russia continued to be a factor behind the diagnostics business's lower full-year revenue. - FY2026-H1WorsenedAnnual report
「In the Diagnostics business, sales of reagents for the PATHFAST mobile immunoassay system and reagents for automated analyzers declined due to lower sales to Russia and a decline in the number of tests conducted in China, among other factors.」
Lower sales to Russia continued to be reflected as a factor behind lower revenue in the diagnostics business. - FY2024RestatedAnnual report
「In connection with the Russia-Ukraine situation, the business domains primarily affected by the impact on sales in Russia are diabetes management and diagnostics and life sciences. As of now, the impact on the Group's overall revenue is minor.」
The impact of the Russia-Ukraine situation on sales in Russia continues to be identified as a risk, but the Group has explained that its impact on the Group as a whole remains minor as of the current fiscal year. - FY2024-Q1First statedAnnual report
「Although sales of antigen test kits for COVID-19 increased in the diagnostics business, sales to Russia stagnated due to the geopolitical impact of the Russia-Ukraine situation, resulting in lower revenue year on year.」
Sales to Russia stagnated due to the geopolitical impact of the Russia-Ukraine situation, resulting in lower revenue in the diagnostics business.